Physician profile
John M Estess
NPI 1497865638
$3,650.21
in general payments reported to CMS, 2019-2025
32 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $181 · 2021: $521 · 2022: $575 · 2023: $583 · 2024: $533 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $577.33 | 2020-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $461.22 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.27 | 2019-2023 | Jardiance |
| Abiomed | $267.12 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $191.03 | 2019-2025 | |
| Thrombolex, INC. | $186.10 | 2025 | Bashir Endovascular Catheter |
| Nuwellis, INC. | $175.99 | 2021-2022 | |
| Boston Scientific Corporation | $160.57 | 2025 | General - Vascular Intervention, Cds - Mct/Cem Monitoring, Ranger |
| Janssen Pharmaceuticals, INC | $140.82 | 2019 | |
| Novo Nordisk INC | $134.06 | 2022-2025 | Ozempic, Rybelsus |
| Bard Peripheral Vascular, INC. | $133.57 | 2025 | Rotarexs 6 F X 135 Cm |
| Amgen INC. | $118.09 | 2020-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $95.24 | 2023-2025 | Amvuttra |
| Cook Medical LLC | $92.25 | 2024 | Zilver Ptx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.05 | 2019-2023 | Lifevest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $84.43 | 2020 | |
| Biotronik INC. | $80.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $65.50 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $56.07 | 2022-2025 | Eliquis, Camzyos |
| Daxor Corporation | $49.69 | 2023 | Bva-100 |
| Lexicon Pharmaceuticals, INC. | $38.78 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $34.50 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $19.92 | 2023 | Optimizer |
| Irhythm Technologies, INC. | $19.01 | 2019 | |
| Daiichi Sankyo INC. | $16.98 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2025 | |
| Akcea Therapeutics, INC. | $16.71 | 2020 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Bracco Diagnostics INC. | $13.47 | 2023 | |
| Portola Pharmaceuticals, LLC | $13.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.94 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Estess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.